Skip to main content
Olema Pharmaceuticals, Inc. logo

Olema Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · OLMA ISIN · US68062P1066 US Manufacturing
Filings indexed 506 across all filing types
Latest filing 2021-08-12 Director's Dealing
Country US United States of America
Listing US OLMA

About Olema Pharmaceuticals, Inc.

https://olema.com/

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. The company concentrates on endocrine-driven diseases, with a primary emphasis on breast cancer. Its lead product candidate, palazestrant (OP-1250), is an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). Palazestrant is under investigation in clinical trials as a potential treatment for patients with ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is advancing a pipeline of drug candidates with the goal of developing improved therapeutic options for cancer patients.

Recent filings

Filing Released Lang Actions
Director's Dealing 2021
Director's Dealing
2021-08-12 English
10-Q
Interim / Quarterly Report Q2 2021
2021-08-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 10, 2021, reporting financial results for the quarter ended June 30, 2021. It references a press release attached as Exhibit 99.1 containing the financial results. The text explicitly states that the press release is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition). The document is short (3894 characters) and primarily serves as a current report filing with a press release attached, not the full financial statements or detailed analysis. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights. It is not a full Interim/Quarterly Report (IR) because it does not contain substantive financial data or statements itself, only a press release. Therefore, the correct classification is Earnings Release (ER).
2021-08-10 English
Director's Dealing 2021
Director's Dealing
2021-07-21 English
Director's Dealing 2021
Director's Dealing
2021-07-14 English
Director's Dealing 2021
Director's Dealing
2021-06-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.